466 related articles for article (PubMed ID: 27798689)
1. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
[TBL] [Abstract][Full Text] [Related]
2. Secretome-based identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell adenocarcinoma.
Arakawa N; Miyagi E; Nomura A; Morita E; Ino Y; Ohtake N; Miyagi Y; Hirahara F; Hirano H
J Proteome Res; 2013 Oct; 12(10):4340-50. PubMed ID: 23805888
[TBL] [Abstract][Full Text] [Related]
3. Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary.
Miyagi E; Arakawa N; Sakamaki K; Yokota NR; Yamanaka T; Yamada Y; Yamaguchi S; Nagao S; Hirashima Y; Kasamatsu Y; Kato H; Mogami T; Miyagi Y; Kobayashi H
Int J Clin Oncol; 2021 Jul; 26(7):1336-1344. PubMed ID: 34009487
[TBL] [Abstract][Full Text] [Related]
4. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics.
Odunsi K; Wollman RM; Ambrosone CB; Hutson A; McCann SE; Tammela J; Geisler JP; Miller G; Sellers T; Cliby W; Qian F; Keitz B; Intengan M; Lele S; Alderfer JL
Int J Cancer; 2005 Feb; 113(5):782-8. PubMed ID: 15499633
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
7. Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix.
Ota Y; Koizume S; Nakamura Y; Yoshihara M; Takahashi T; Sato S; Myoba S; Ohtake N; Kato H; Yokose T; Miyagi E; Miyagi Y
Oncol Rep; 2021 Mar; 45(3):1023-1032. PubMed ID: 33650653
[TBL] [Abstract][Full Text] [Related]
8. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study.
Wu J; Yin H; Zhu J; Buckanovich RJ; Thorpe JD; Dai J; Urban N; Lubman DM
PLoS One; 2015; 10(3):e0121112. PubMed ID: 25799488
[TBL] [Abstract][Full Text] [Related]
9. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
Barlow TS; Przybylski M; Schilder JM; Moore DH; Look KY
Int J Gynecol Cancer; 2006; 16(2):496-500. PubMed ID: 16681717
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer.
Zou L; He X; Zhang JW
Braz J Med Biol Res; 2010 Dec; 43(12):1232-8. PubMed ID: 21103788
[TBL] [Abstract][Full Text] [Related]
11. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
12. Preoperative measurement of serum C-reactive protein: is it useful in the differential diagnosis of adnexal masses?
Yoshida A; Derchain SF; Pitta DR; Crozatti N; Andrade LALA; da Silva RF; Sarian LO
Int J Biol Markers; 2017 Mar; 32(1):e83-e89. PubMed ID: 27516000
[TBL] [Abstract][Full Text] [Related]
13. Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors.
Miyagi E; Maruyama Y; Mogami T; Numazaki R; Ikeda A; Yamamoto H; Hirahara F
Int J Clin Oncol; 2017 Feb; 22(1):118-125. PubMed ID: 27623814
[TBL] [Abstract][Full Text] [Related]
14. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
Li QL; Wang CJ; Qi P; Zhang YX
Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
[TBL] [Abstract][Full Text] [Related]
15. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
[TBL] [Abstract][Full Text] [Related]
16. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
[TBL] [Abstract][Full Text] [Related]
17. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
Karlsen MA; Fagö-Olsen C; Høgdall E; Schnack TH; Christensen IJ; Nedergaard L; Lundvall L; Lydolph MC; Engelholm SA; Høgdall C
Tumour Biol; 2016 Sep; 37(9):12619-12626. PubMed ID: 27440204
[TBL] [Abstract][Full Text] [Related]
18. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
[TBL] [Abstract][Full Text] [Related]
19. Serum soluble mesothelin-related peptide (SMRP): a potential diagnostic and monitoring marker for epithelial ovarian cancer.
Wu X; Li D; Liu L; Liu B; Liang H; Yang B
Arch Gynecol Obstet; 2014 Jun; 289(6):1309-14. PubMed ID: 24370956
[TBL] [Abstract][Full Text] [Related]
20. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.
Arits AH; Stoot JE; Botterweck AA; Roumen FJ; Voogd AC
Int J Gynecol Cancer; 2008; 18(4):621-8. PubMed ID: 17868339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]